Patents Assigned to Turning Point Therapeutics, Inc.
-
Patent number: 11666574Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.Type: GrantFiled: November 25, 2020Date of Patent: June 6, 2023Assignee: Turning Point Therapeutics, Inc.Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui, Nathan V. Lee
-
Patent number: 11654145Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.Type: GrantFiled: November 25, 2020Date of Patent: May 23, 2023Assignee: Turning Point Therapeutics, Inc.Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui
-
Patent number: 11634433Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.Type: GrantFiled: December 2, 2020Date of Patent: April 25, 2023Assignee: TURNING POINT THERAPEUTICS, INC.Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
-
Patent number: 11452725Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.Type: GrantFiled: August 20, 2020Date of Patent: September 27, 2022Assignee: TURNING POINT THERAPEUTICS, INC.Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Zhongdong Huang
-
Patent number: 11291667Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.Type: GrantFiled: January 25, 2018Date of Patent: April 5, 2022Assignee: TURNING POINT THERAPEUTICS, INC.Inventors: Jingrong Jean Cui, Dayong Zhai
-
Patent number: 11286265Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.Type: GrantFiled: May 5, 2020Date of Patent: March 29, 2022Assignee: TURNING POINT THERAPEUTICS, INC.Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
-
Patent number: 11286264Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.Type: GrantFiled: July 26, 2018Date of Patent: March 29, 2022Assignee: TURNING POINT THERAPEUTICS, INC.Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
-
Patent number: 11155563Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.Type: GrantFiled: March 25, 2021Date of Patent: October 26, 2021Assignee: Turning Point Therapeutics, Inc.Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
-
Patent number: 11142533Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.Type: GrantFiled: March 26, 2021Date of Patent: October 12, 2021Assignee: Turning Point Therapeutics, Inc.Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
-
Patent number: 11008337Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, of the formula I: pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.Type: GrantFiled: May 29, 2019Date of Patent: May 18, 2021Assignee: Turning Point Therapeutics, Inc.Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Jane Ung
-
Patent number: 10745416Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.Type: GrantFiled: January 30, 2020Date of Patent: August 18, 2020Assignee: Turning Point Therapeutics, Inc.Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
-
Patent number: 10689400Abstract: The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.Type: GrantFiled: July 27, 2017Date of Patent: June 23, 2020Assignee: Turning Point Therapeutics, Inc.Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Jane Ung
-
Publication number: 20200190110Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.Type: ApplicationFiled: January 30, 2020Publication date: June 18, 2020Applicant: Turning Point Therapeutics, Inc.Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
-
Patent number: 10618912Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.Type: GrantFiled: November 29, 2018Date of Patent: April 14, 2020Assignee: Turning Point Therapeutics, Inc.Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai